FENNEC PHARMACEUTICALS INC's ticker is FENC and the CUSIP is 31447P100. A total of 57 filers reported holding FENNEC PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 1.69 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $19,500,000 | +45.2% | 2,407,357 | 0.0% | 13.24% | +61.5% |
| Q2 2022 | $13,433,000 | -0.4% | 2,407,357 | 0.0% | 8.20% | +8.2% |
| Q1 2022 | $13,481,000 | +27.3% | 2,407,357 | 0.0% | 7.58% | +10.4% |
| Q4 2021 | $10,592,000 | -53.3% | 2,407,357 | 0.0% | 6.86% | -46.4% |
| Q3 2021 | $22,677,000 | +27.8% | 2,407,357 | -1.1% | 12.81% | +877.3% |
| Q2 2021 | $17,738,000 | +17.4% | 2,433,230 | 0.0% | 1.31% | -79.0% |
| Q1 2021 | $15,110,000 | -16.6% | 2,433,230 | 0.0% | 6.24% | -28.8% |
| Q4 2020 | $18,128,000 | +83.0% | 2,433,230 | +48.8% | 8.76% | +25.8% |
| Q3 2020 | $9,906,000 | -27.4% | 1,634,689 | 0.0% | 6.96% | +2.5% |
| Q2 2020 | $13,650,000 | +175.3% | 1,634,689 | +95.8% | 6.79% | +58.1% |
| Q1 2020 | $4,958,000 | -8.5% | 834,689 | 0.0% | 4.30% | -22.8% |
| Q4 2019 | $5,417,000 | – | 834,689 | – | 5.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Solas Capital Management, LLC | 849,979 | $3,400,000 | 3.47% |
| Southpoint Capital Advisors LP | 3,997,214 | $15,989,000 | 0.60% |
| Opaleye Management Inc. | 295,000 | $1,180,000 | 0.36% |
| 683 Capital Management, LLC | 971,351 | $3,885,000 | 0.35% |
| Avoro Capital Advisors LLC | 1,105,999 | $4,424,000 | 0.15% |
| Eventide Asset Management | 720,000 | $2,880,000 | 0.09% |
| Granahan Investment Management | 439,083 | $1,756,000 | 0.09% |
| Hartford Financial Management Inc. | 20,300 | $81,000 | 0.03% |
| OXFORD ASSET MANAGEMENT LLP | 75,236 | $301,000 | 0.01% |
| Paloma Partners Management Co | 54,400 | $218,000 | 0.00% |